Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Y Tokuda
Total Records ( 2 ) for Y Tokuda
  Y Yamamoto , S Yamazaki , Y Hayashino , O Takahashi , Y Tokuda , T Shimbo , T Fukui , S Hinohara , Y Miyachi and S. Fukuhara
 

Objective  To evaluate the relationship between frequency of pruritic symptoms experienced over a 1-month period and psychological stress.

Design  Cohort study.

Setting  Population-based study in Japan.

Participants  A total of 2224 participants at least 18 years old and without psychiatric disorders participated in the Japan Health Diary Study (October 2003), a cohort study comprising a representative sample in Japan.

Main Outcome Measures  Frequency of pruritic symptoms assessed by self-reported health diaries over the 1-month period and subsequent psychological stress measured using the Japanese version of the Perceived Stress Scale.

Results  The 2224 participants had a mean age of 44.6 years, 1212 (54.5%) were women, and 70 (3.1%) presented with pruritic symptoms. Multivariable analysis showed that patients with pruritic symptoms had significantly higher psychological stress than those without pruritic symptoms (β coefficient, 2.33; 95% confidence interval [CI], 0.53-4.14; P = .01). Furthermore, a linear trend was observed between increased psychological stress and increased severity of pruritic symptoms, with β coefficients for the first, second, and third tertiles for symptoms of 0.81 (95% CI, –1.97 to 3.59), 1.77 (95% CI, –0.82 to 4.37), and 4.86 (95% CI, 1.29 to 8.43), respectively (P value for trend, .004).

Conclusion  Our results suggest that frequency of pruritic symptoms is associated with psychological stress in the general population.

  Y Suzuki , Y Tokuda , Y Fujiwara , H Iwata , Y Sasaki , S Saji , K Aogi , Y Nambu , A Suri , T Saeki and S. Takashima
  Objective

This Phase II study was conducted to evaluate efficacy and safety of gemcitabine monotherapy in anthracycline and taxane pre-treated Japanese metastatic breast cancer patients.

Methods

At Step 1, twelve patients were divided into two groups of six patients each and the dose-limiting toxicity was evaluated at gemcitabine 1000 and 1250 mg/m2 to determine the dose for Step 2. At Step 2, an additional 56 patients were assessed for efficacy and safety of gemcitabine monotherapy. Patients were treated with gemcitabine on days 1 and 8 of a 21-day cycle and explored incidence of adverse events graded by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, overall response rate (RR), time to progression disease and overall survival time.

Results

Gemcitabine 1250 mg/m2 was determined as the dose for Step 2. Adverse events reported in this study were similar in type, frequency and toxicity grades as seen in other tumor types. Of the 62 patients at 1250 mg/m2, 1 complete response (1.6%), 4 partial response (6.5%) and 20 stable disease (32.3%) were achieved, yielding an RR of 8.1% (95% CI: 2.7%, 17.8%). Median time to progression was 92.0 days (range: 29–651 days). The median survival time was 17.8 months (95% CI: 14.9 months to incalculable).

Conclusion

Gemcitabine at 1250 mg/m2 on days 1 and 8 of a 21-day cycle was tolerable and can be a salvage treatment option for Japanese metastatic breast cancer patients previously treated with anthracyclines and taxanes.

 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility